Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Revenue: 2021-2024

Historic Revenue for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $89.1 million.

  • ARS Pharmaceuticals' Revenue rose 1471.62% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.8 million, marking a year-over-year increase of 5395.46%. This contributed to the annual value of $89.1 million for FY2024, which is 297063.33% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Revenue stood at $89.1 million for FY2024, which was up 297,063.33% from $30,000 recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Revenue ranged from a high of $89.1 million in FY2024 and a low of $30,000 during FY2023.
  • For the 3-year period, ARS Pharmaceuticals' Revenue averaged around $30.2 million, with its median value being $1.3 million (2022).
  • Its Revenue has fluctuated over the past 5 years, first slumped by 97.72% in 2023, then soared by 297,063.33% in 2024.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Revenue stood at $5.5 million in 2021, then plummeted by 76.10% to $1.3 million in 2022, then tumbled by 97.72% to $30,000 in 2023, then skyrocketed by 297,063.33% to $89.1 million in 2024.